Question 1

What is Annovis Bio?

Accepted Answer

Annovis Bio is a Company.

Question 2

How often does Annovis Bio appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 14 articles.

Question 3

When was Annovis Bio first tracked by Ergen?

Accepted Answer

First tracked on Apr 02, 2026.

Question 4

When was Annovis Bio last mentioned in news?

Accepted Answer

Last active on Aug 14, 2026.

Question 5

What is Annovis Bio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Annovis Bio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Annovis Bio?

Accepted Answer

Annovis Bio secures buntanetap patent (Apr 02, 2026, 8 articles).

Question 8

How did the "Annovis Bio secures buntanetap patent" event impact Annovis Bio?

Accepted Answer

Annovis Bio secured a U.S. patent for its investigational therapy, buntanetap, which is expected to enhance its intellectual property estate and potential market reach for treating neurodegenerative diseases.

Question 9

How did the "Annovis Bio Phase 3 AD Trial Fully Enrolled" event impact Annovis Bio?

Accepted Answer

Annovis Bio is the central entity, achieving full enrollment in its pivotal Phase 3 AD trial and advancing its pipeline. The company's financial position remains tight with $18.7 million cash, but the clinical progress could enhance its valuation if data are positive.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.